Lento Bio Inc. has synthesized cysteine derivatives reported to be useful for the treatment of presbyopia. An exemplified compound (Cpd in row 4 in tbl1 pg 20, claim 18) decreased in lens stiffness in C57BL/6 mice (at 20 mM; as eye drops).
Iregene Therapeutics (Suzhou) Co. Ltd. has identified pyrazolecarbonyl piperazinone compounds acting as bone morphogenetic protein receptor type-1B (BMPR1B) inhibitors reported to be useful for the treatment of cancer and pulmonary hypertension.
B7H3 is a pan-cancer antigen considered a promising target for immunotherapy. However, targeting B7H3 using bispecific T-cell engagers (BiTEs) presents the problem of systemic toxicity.
SK Biopharmaceuticals Co. Ltd. has signed a research collaboration agreement with Proen Therapeutics Inc. to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with on-target off-tumor toxicities due to the expression of the target in normal myeloid cells. A subset of T cells – Vδ2 T-cells – which represent ~5% of the T-cell population in healthy donors, are seen as part of emerging immunotherapeutic strategies.
Verge Genomics (Verge Analytics Inc.) has nominated a second development candidate, VRG-201, targeting long-term weight management and metabolic homeostasis. VRG-201 is an oral, first-in-class small-molecule therapy that targets the underlying metabolic pathways leading to abnormal weight gain and the development or worsening of obesity.
In tumoral cells, the modulation of the G1/S phases of cell cycle is destabilized by amplification and high expression of cyclin E (CCNE) or by mutation or loss of retinoblastoma 1 (RB1) gene. Cancer cells meeting these characteristics have been sown to be highly sensitive to cyclin-dependent kinase 2 (CDK2) depletion.
Candid Therapeutics Inc. has entered into a number of collaborations aimed at advancing its pipeline of T-cell engagers (TCEs) for autoimmune diseases. The company will be collaborating with Epimab Biotherapeutics Inc., Ab Studio Inc. and Nona Biosciences.
RSS
